Identifying patients with NTRK fusion cancer

Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, J P, Benayed, R, Hechtman, J F, Ladanyi, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859817/
https://www.ncbi.nlm.nih.gov/pubmed/31738428
http://dx.doi.org/10.1093/annonc/mdz384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859817/
https://www.ncbi.nlm.nih.gov/pubmed/31738428
http://dx.doi.org/10.1093/annonc/mdz384

Ejemplares similares